NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo

Keiko Sato; Kiyoshi Morimoto; Norihito Yamada; Shigetoshi Kuroda; Toshiyuki Hayabara

doi:10.1016/0006-8993(95)00266-S

NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo

Keiko Sato, Kiyoshi Morimoto, Norihito Yamada, Shigetoshi Kuroda, Toshiyuki Hayabara

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline), a selective antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, at an anticonvulsant dose of 40 mg/kg (i.p.), was shown in vivo to have no effects on either the field potentials in the piriform cortex or those in the dentate gyrus of the hippocampus. The same dose of NBQX also exerted no significant effects on long-term potentiation in the hippocampus. These results suggest that the mechanism underlying the anticonvulsant action of NBQX in vivo does not involve a suppressive action on physiological synaptic transmission. The possible clinical usefulness of AMPA receptor antagonists as antiepiletic drugs is suggested.

Original language	English
Pages (from-to)	279-282
Number of pages	4
Journal	Brain Research
Volume	683
Issue number	2
DOIs	https://doi.org/10.1016/0006-8993(95)00266-S
Publication status	Published - Jun 19 1995

Keywords

Field potential
In vivo
Long-term potentiation
NBQX
Selective AMPA receptor antagonist

ASJC Scopus subject areas

Neuroscience(all)
Molecular Biology
Clinical Neurology
Developmental Biology

Access to Document

10.1016/0006-8993(95)00266-S

Fingerprint Dive into the research topics of 'NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo'. Together they form a unique fingerprint.

Cite this

@article{b586a399c2654c99b95ca837dd38eda0,

title = "NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo",

abstract = "NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline), a selective antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, at an anticonvulsant dose of 40 mg/kg (i.p.), was shown in vivo to have no effects on either the field potentials in the piriform cortex or those in the dentate gyrus of the hippocampus. The same dose of NBQX also exerted no significant effects on long-term potentiation in the hippocampus. These results suggest that the mechanism underlying the anticonvulsant action of NBQX in vivo does not involve a suppressive action on physiological synaptic transmission. The possible clinical usefulness of AMPA receptor antagonists as antiepiletic drugs is suggested.",

keywords = "Field potential, In vivo, Long-term potentiation, NBQX, Selective AMPA receptor antagonist",

author = "Keiko Sato and Kiyoshi Morimoto and Norihito Yamada and Shigetoshi Kuroda and Toshiyuki Hayabara",

year = "1995",

month = jun,

day = "19",

doi = "10.1016/0006-8993(95)00266-S",

language = "English",

volume = "683",

pages = "279--282",

journal = "Brain Research",

issn = "0006-8993",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo

AU - Sato, Keiko

AU - Morimoto, Kiyoshi

AU - Yamada, Norihito

AU - Kuroda, Shigetoshi

AU - Hayabara, Toshiyuki

PY - 1995/6/19

Y1 - 1995/6/19

N2 - NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline), a selective antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, at an anticonvulsant dose of 40 mg/kg (i.p.), was shown in vivo to have no effects on either the field potentials in the piriform cortex or those in the dentate gyrus of the hippocampus. The same dose of NBQX also exerted no significant effects on long-term potentiation in the hippocampus. These results suggest that the mechanism underlying the anticonvulsant action of NBQX in vivo does not involve a suppressive action on physiological synaptic transmission. The possible clinical usefulness of AMPA receptor antagonists as antiepiletic drugs is suggested.

AB - NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline), a selective antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, at an anticonvulsant dose of 40 mg/kg (i.p.), was shown in vivo to have no effects on either the field potentials in the piriform cortex or those in the dentate gyrus of the hippocampus. The same dose of NBQX also exerted no significant effects on long-term potentiation in the hippocampus. These results suggest that the mechanism underlying the anticonvulsant action of NBQX in vivo does not involve a suppressive action on physiological synaptic transmission. The possible clinical usefulness of AMPA receptor antagonists as antiepiletic drugs is suggested.

KW - Field potential

KW - In vivo

KW - Long-term potentiation

KW - NBQX

KW - Selective AMPA receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=0028997310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028997310&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(95)00266-S

DO - 10.1016/0006-8993(95)00266-S

M3 - Article

C2 - 7552367

AN - SCOPUS:0028997310

VL - 683

SP - 279

EP - 282

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -